HCM - Hutchmed inks Tazverik development deal with Epizyme in Greater China

Hutchmed (NASDAQ:HCM) has collaborated with Epizyme (NASDAQ:EPZM) to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). TAZVERIK is a methyltransferase inhibitor of EZH2 developed by Epizyme that is approved by the FDA for the treatment of patients with epithelioid sarcoma (ES) and follicular lymphoma (FL). Under the terms of the agreement, Hutchmed will be responsible for the development and commercialization of TAZVERIK in greater China and will be responsible for funding all clinical trials in the Territory. Epizyme will receive a $25M upfront payment and is eligible to receive up to an additional $110M in development and regulatory milestone payments, across up to eight potential indications, and up to an additional $175M in sales milestone payments. Epizyme is also eligible to receive tiered royalties of mid -teen to low-twenties-percent based on annual net sales of TAZVERIK in Greater China. In addition, Hutchmed receives a four-year

For further details see:

Hutchmed inks Tazverik development deal with Epizyme in Greater China